BioVie
BioVie is dedicated to developing innovative treatments for aging-related diseases, neurodegenerative disorders, and advanced liver disease. Their mission is to unlock the science of longevity and beyond, aiming to discover new cures and improve patient lives through their flagship molecule, bezisterim (NE3107), which targets chronic inflammation and metabolic dysregulation. The company is actively engaged in clinical trials for conditions such as Alzheimer’s, Parkinson’s, Long COVID, and ascites, and is committed to scientific progress and transformative healthcare solutions.
Industries
Nr. of Employees
small (1-50)
BioVie
Beverly, Massachusetts, United States, North America
Patents
Products
Bezisterim (NE3107)
An orally administered, blood–brain barrier permeable small molecule described as having anti-inflammatory and insulin-sensitizing activity via modulation of ERK/NF‑κB signaling; evaluated in clinical trials for neurologic indications and for effects on DNA methylation.
BIV201 (continuous infusion terlipressin formulation)
A continuous infusion liquid formulation of terlipressin developed for outpatient treatment of refractory ascites and delivered via a small wearable infusion pump.
Bezisterim (NE3107)
An orally administered, blood–brain barrier permeable small molecule described as having anti-inflammatory and insulin-sensitizing activity via modulation of ERK/NF‑κB signaling; evaluated in clinical trials for neurologic indications and for effects on DNA methylation.
BIV201 (continuous infusion terlipressin formulation)
A continuous infusion liquid formulation of terlipressin developed for outpatient treatment of refractory ascites and delivered via a small wearable infusion pump.
Services
Planning and running randomized, placebo-controlled Phase 2/3 clinical trials with biomarker, imaging, PK, and safety endpoints; supports hybrid/decentralized participation.
Preclinical efficacy, PK, and safety studies in animal models including non-human primates to support translational development.
Planning and running randomized, placebo-controlled Phase 2/3 clinical trials with biomarker, imaging, PK, and safety endpoints; supports hybrid/decentralized participation.
Preclinical efficacy, PK, and safety studies in animal models including non-human primates to support translational development.
Expertise Areas
- Clinical trial management
- Neurology drug development
- Hepatology and ascites therapeutics
- Biomarker and epigenetics research
Key Technologies
- Oral CNS-penetrant small-molecule therapeutics
- Continuous infusion via wearable pump
- Liquid peptide/drug formulation stability
- DNA methylation / epigenetic clocks
News & Updates
Presented safety and tolerability of continuous infusion terlipressin (BIV201) in patients with decompensated cirrhosis and refractory ascites in a Phase 2 study.
Presented clinical outcomes from a Phase 3 trial of NE3107 in subjects with mild to moderate probable Alzheimer’s disease.
Presented effects of NE3107 on motor activity and neurodegenerative features in Parkinson’s disease in a marmoset monkey model.
Presented safety and tolerability of continuous infusion terlipressin (BIV201) in patients with decompensated cirrhosis and refractory ascites in a Phase 2 study.
Presented clinical outcomes from a Phase 3 trial of NE3107 in subjects with mild to moderate probable Alzheimer’s disease.
Presented effects of NE3107 on motor activity and neurodegenerative features in Parkinson’s disease in a marmoset monkey model.